Mivel semmit sem találtál, itt van pár példa.
Ivermectin:
Fig. 2. Major dimensions of COVID-19 infection that call for a multi-drug strategy in the early ambulatory period with available medications including anti-infectives (hydroxychloroquine, ivermectin, azithromycin, doxycycline), corticosteroids, and anti-platelet drugs and anticoagulants. The three dimensionsof the infection and their time-course allow for the sequenced multi-drug approach to be utilized with the goal of reducing hospitalization and death.
5. Ivermectin
Ivermectin (IVM) is a broad spectrum anti-parasitic agent
that has been shown to have anti-viral activity against a range
of viruses including recently, SARS-CoV-2 (Heidary and Ghare-
baghi, 2020). This drug is well tolerated, has a high therapeutic
index and proven safety profile with over 3.7 billion treatments,
and has been used alone or combined with either doxycycline or
azithromycin in early clinical studies of patients with COVID-19
(Rahman et al., 2020). There are a number of randomized and
prospective studies and all have shown efficacy in clinical out-
comes at the time of this report (Alam et al., 2020; Chowdhury
et al., 2020; Gorial et al., 2020; Khan et al., 2020; Nunez et al.,
2020). Hence, it is reasonable in patients where HCQ cannot be
used and favipiravir is not available, that IVM (200-600 mcg/kg
[6-36 mg] single oral dose given daily or every other day for 2-
3 administrations) could be the base of SMDT intended to reduce
viral replication early in the course of COVID-19. However, uncer-
tainty remains at this time concerning optimal dosing and schedule
(Schmith et al., 2020). In the ICON study, IVM use in the hospi-
tal was associated with a 48% relative risk reduction in COVID-19
mortality (Rajter et al., 2020). Currently, there are 36 randomized
clinical trials of ivermectin alone or in combination for ambulatory
and hospitalized patients listed on clinicaltrials.gov.Doxycycline is another common antibiotic with multiple intra-
cellular effects that may reduce viral replication, cellular damage,
and expression of inflammatory factors (Malek et al., 2020; Sodhi
and Etminan, 2020).
...
When combined
with ivermectin early in the infection it appears to enhance effi-
cacy to near complete eradication of COVID-19 in less than 10
days.
D vitamin:
Vitamin D deficiency has been associated with increased
COVID-19 mortality and is commonly confounded by increas-
ing age, obesity, diabetes, darker skin tones, and lack of fitness
(Meltzer et al., 2020; Pereira et al., 2020) With good rationale, one
small, randomized trial of vitamin D 3 supplementation found re-
duced mortality in patients with COVID-19 (Entrenas et al., 2020;
Zhang et al., 2020a). The suggested dose is 5000 IU of vitamin
D 3 per day.